A late-stage trial of the experimental antibiotic ceftobiprole, which is being jointly developed by Basilea and J&J, has demonstrated significant results, with 86 percent of patients being cured of diabetic foot infections. The therapy, which is under review at the FDA, also demonstrated signs of success against antibiotic-resistant bacteria, or Staphylococcus aureus. Researchers unveiled the data at the Infectious Disease Society of America meeting in San Diego.
"Diabetic foot infections are becoming increasingly difficult to treat," said study author, Gary J. Noel, M.D., with Johnson & Johnson Pharmaceutical Research & Development. "These data suggest that ceftobiprole may be useful as stand-alone therapy for this increasingly common type of complicated skin infection."
- check out the release for more info